STAT6h
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Merck Expands Oncology Pipeline By Securing License For LaNova Medicines' LM-299
Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...
unite14d
10 Best AI Logo Generators (November 2024)
Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...
Seeking Alpha20d
Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key ...
NDTV21d
US Health Advisers Back Pfizer, Merck Pneumonia Shots For Adults Over 50
US Health Advisers Back Pfizer, Merck Pneumonia Shots For Adults Over 50 Both Pfizer and Merck had asked the CDC to lower age recommendations to include adults 50 and up. Madison Muller, Bloomberg ...
Outsourcing-pharma21d
Merck acquires cancer startup in a deal worth up to $1.3 billion
Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair processes. Modifi Biosciences, a spin out of Yale University founded in 2021, ...
BioSpace21d
Modifi Biosciences Acquired by Merck
Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company ...
FiercePharma22d
In boon for Pfizer and Merck, CDC panel backs expanded use of pneumococcal vaccines
In a 14-1 vote, the panel moved to expand its usage recommendation for both Pfizer’s Prevnar 20 and Merck’s Capvaxive to include all adults aged 50 and older as well as adults between 19 and ...
Reuters22d
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 bln
Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...
U.S. News & World Report22d
Merck Buys Cancer Therapy Developer Modifi Biosciences for up to $1.3 Billion
(Reuters) - Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of ...
FierceBiotech22d
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).